Epeius Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine
News Feb 17, 2009
Epeius Biotechnologies Corporation has received two additional European patents for the platform targeting technologies and molecular designs that enable precision gene delivery to primary cancers and metastatic lesions that have spread throughout the body.
With profound demonstrations of clinical benefit and single-agent-efficacy, as well as overall safety, Epeius Biotech continues to lead the field of clinical gene medicine with the advent of pathotropic (or disease-seeking) targeting. These latest EU patents follow on the heels of a major clinical patent that was recently awarded in the USA for targeted gene delivery in vivo.
Together these clinical patents provide additional intellectual property protection for the platform of highly advanced biotechnologies embodied in the company’s leading anti-cancer agent Rexin-G®—the first and so far only tumor-targeted gene delivery system that has been successfully validated in the clinic.
Based on recent breakthroughs in tumor-targeting and nanotechnology, a new generation of biological anti-cancer agents that are highly selective for diseased tissues is currently in clinical development.
Anti-cancer agents such as Rexin-G® can be delivered by simple intravenous infusion, yet are programmed to seek-out and accumulate selectively in primary and metastatic lesions that have spread throughout the body, delivering a tumor-killing gene while sparing normal cells and tissues.
Revolutionary Imaging Technique Uses CRISPR to Map DNA MutationsNews
The new high-speed AFM method can map DNA to a resolution of tens of base pairs while creating images up to a million base pairs in size. And it does it using a fraction of the amount of specimen required for DNA sequencing.READ MORE
AIDS Vaccine Design: New Data Offers Important InsightNews
New data published in Immunity further illuminate how some human beings generate powerful, HIV-blocking antibodies. The results offer important insight into a potential AIDS vaccine design.READ MORE